The 14th Swiss Course on Medicinal Chemistry addresses most up-to-date topics of current pharmaceutical research in different areas, such as:

  • New Chemical Space utilized for Medicinal Chemistry Applications
  • Medicinal Chemistry Approaches towards prominent Target Families
  • Technologies and Tactics applied in Lead Finding and Optimization
  • Case Stories of successful small-molecule drug discovery

The organizers are proud to announce that a considerable number of renowned experts in their respective research field will contribute to this year’s Medicinal Chemistry Academy. Attendees will get authentic insights into emerging areas of small-molecule drug discovery, presented by inspiring world-class opinion leaders from innovative biotechnology companies, big pharma industry, and prestigious academic research groups, some of which are mentioned below. A broad spectrum of enabling technologies and drug discovery success stories across different disease areas will be presented.

Dr. Sabine Hadida, Vice President at Vertex Pharmaceuticals, will present a compelling story centered around the long and windy discovery route of a life-changing therapy, namely the Cystis Fibrosis drug portfolio, developed over the last years at Vertex. This will be a breath-taking medicinal chemistry success story touching upon numerous interdisciplinary aspects such as phenotypic screening and personalized medicine.

A comprehensive overview on therapeutic approaches in the field of cancer treatment will be provided by a true expert and practitioner in the field, namely Dr. Andrew Mortlock, Vice President Oncology Projects and Alliances at AstraZeneca. A broad spectrum of drug discovery opportunities in the field of oncology with associated medicinal chemistry strategies will be presented. This is a Must-Hear Topic for all practitioners in our scientific research field.

Dr. Robert Copeland, Chief Scientific Officer of Accent Therapeutics, one of the pioneering biotechnology companies exploring the field of epitranscriptomics, will contribute with an inspirational lecture on most modern aspects of drug discovery both, from a therapeutic perspective and a technology point of view.

As one of the world-leading experts in Medicinal Chemistry, Dr. Nicholas A. Meanwell, Vice President at Bristol-Myers Squibb, will provide a detailed report on truly successful drug discovery campaign pursued at BMS that yielded in an innovative breakthrough medicine. In addition to reporting on that success story, he will actively teach on the tactical application of bio-isosteric concepts in Lead Finding and Optimization during hands-on tutorials, all attendees will participate in.

Dr. Andy Phillips, Chief Executive Officer and President at C4 Therapeutics will introduce the concept of Targeted Protein Degradation in which synthetic conjugates of linked protein ligands are utilized to harness the innate power of the human organism to eliminate disease-causing proteins. This breakthrough technology offers several advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.

The detailed aspects of thermodynamics and kinetics involved in the process of molecular recognition, and aspects of target engagement and drug action will be highlighted by world-leading specialists in the field of biophysical, crystallographic, pharmacological, and computational investigations of drug-target interactions, i.e. Prof. Dr. Gerhard Klebe, Universisty of Marburg.and Prof. Dr. Peter Tonge, Stony Brook University, New York. They will highlight widely under-appreciated optimization parameters the medicinal chemistry community needs to get better acquainted with in the future.